Analyst predicts blockbuster potential for Biomarin's growth hormone
![Photo: Anders Rye Skjoldjensen](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13469015.ece/ALTERNATES/schema-16_9/doc7ifmpkwmend14t473yz.jpg)
Within the week, Biomarin will know whether it has received the green light to market Voxzogo – its treatment for achondroplasia, also known as dwarfism – from the US Food and Drug Administration (FDA).
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.